2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Melanoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
lutetium Lu 177 dotatate
8
lanreotide
4
copper dotatate CU-64
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
pasireotide
3
Magnetic Resonance Spectroscopy
3
Lutetium-177
3
Lutetium
3
gallium Ga 68 dotatate
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
Irinotecan
2
Ga(III)-DOTATOC
2
Everolimus
2
Etoposide
2
Carboplatin
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
irinotecan sucrosofate
1
folfirinox
1
famitinib
1
cabozantinib
1
arginyllysine
1
abemaciclib
1
X-Rays
1
Sunitinib
1
Somatostatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
zimberelimab
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled